Modular antibody platform Abzyme Therapeutics offers a proprietary modular single domain VHH antibody platform with yeast display libraries and rapid affinity maturation, presenting a compelling selling point to potential partners seeking customizable immunotherapy and diagnostic solutions.

Therapeutic and diagnostic pipeline With over 60 proprietary and partnered programs across infectious diseases, immuno-oncology, ophthalmology, inflammation, and CNS disorders, there are multiple collaboration angles for co-development, licensing, and funded research opportunities.

Strategic location Located in the Eastern Pennsylvania biotech hub near Philadelphia, Abzyme is positioned to leverage regional networks for partnerships, contract research, and access to nearby academic and clinical collaboration opportunities.

SBIR/DoD interest Past SBIR Phase II engagement and DoD-funded antibody development initiatives indicate readiness for government-funded collaborations and milestone-driven programs with potential for grant-supported development.

Early-stage focus Small team size and revenue scale suggest a nimble partner for early-stage co-development, technology licensing, and research collaborations that leverage their discovery platform before larger pharma-scale commitments.